NASDAQ:IMTX Immatics (IMTX) Stock Price, News & Analysis $6.65 +0.04 (+0.61%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$6.55 -0.10 (-1.50%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immatics Stock (NASDAQ:IMTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immatics alerts:Sign Up Key Stats Today's Range$6.51▼$6.6650-Day Range$5.14▼$6.6852-Week Range$3.30▼$13.09Volume243,055 shsAverage Volume394,198 shsMarket Capitalization$808.31 millionP/E RatioN/ADividend YieldN/APrice Target$14.67Consensus RatingBuy Company Overview Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany. Read More Immatics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreIMTX MarketRank™: Immatics scored higher than 44% of companies evaluated by MarketBeat, and ranked 1244th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingImmatics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmatics has only been the subject of 1 research reports in the past 90 days.Read more about Immatics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immatics are expected to decrease in the coming year, from ($0.72) to ($1.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immatics is -39.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immatics is -39.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmatics has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immatics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.15% of the outstanding shares of Immatics have been sold short.Short Interest Ratio / Days to CoverImmatics has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Immatics has recently decreased by 5.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmatics does not currently pay a dividend.Dividend GrowthImmatics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.15% of the outstanding shares of Immatics have been sold short.Short Interest Ratio / Days to CoverImmatics has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Immatics has recently decreased by 5.90%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 3 people have searched for IMTX on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows3 people have added Immatics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immatics insiders have not sold or bought any company stock.Percentage Held by Institutions64.41% of the stock of Immatics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immatics' insider trading history. Receive IMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter. Email Address IMTX Stock News HeadlinesHere Is What You Need To Know Before Investing In Immatics N.V. (IMTX)July 9, 2025 | insidermonkey.comImmatics N.V. (IMTX) Earnings Surprise Summary (EPS) - Seeking AlphaJune 26, 2025 | seekingalpha.comIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ years of navigating crashes and crises, he says traditional strategies could soon become wealth destroyers. A time-sensitive briefing reveals what to do now. | InvestorPlace (Ad)Immatics N.V. Shareholders Approve Key Resolutions at June 2025 AGMJune 18, 2025 | tipranks.comImmatics: Taking Off On A PRAME RocketshipJune 4, 2025 | seekingalpha.comImmatics rises on data from early stage cell therapy trialJune 2, 2025 | msn.comImmatics Presents Promising IMA203 Data at ASCO 2025June 2, 2025 | tipranks.comImmatics (IMTX) Shares Promising Data from IMA203 Melanoma Trials | IMTX Stock NewsJune 1, 2025 | gurufocus.comSee More Headlines IMTX Stock Analysis - Frequently Asked Questions How have IMTX shares performed this year? Immatics' stock was trading at $7.11 at the start of the year. Since then, IMTX stock has decreased by 6.5% and is now trading at $6.65. How were Immatics' earnings last quarter? Immatics N.V. (NASDAQ:IMTX) released its earnings results on Tuesday, May, 13th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.04. The business earned $20.12 million during the quarter, compared to the consensus estimate of $14.92 million. Immatics had a negative net margin of 14.73% and a negative trailing twelve-month return on equity of 4.52%. Who are Immatics' major shareholders? Top institutional shareholders of Immatics include TD Asset Management Inc (0.24%), Vanguard Personalized Indexing Management LLC (0.04%), Simplex Trading LLC and Vontobel Holding Ltd. (0.01%). How do I buy shares of Immatics? Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immatics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immatics investors own include Broadcom (AVGO), Datadog (DDOG), Advanced Micro Devices (AMD), Moderna (MRNA), Cloudflare (NET) and QUALCOMM (QCOM). Company Calendar Last Earnings5/13/2025Today8/06/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMTX CIK1809196 Webwww.immatics.com Phone4.97072E+12FaxN/AEmployees260Year FoundedN/APrice Target and Rating Average Price Target for Immatics$14.67 High Price Target$19.00 Low Price Target$10.00 Potential Upside/Downside+120.6%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$16.47 million Net Margins-14.73% Pretax Margin-11.63% Return on Equity-4.52% Return on Assets-3.34% Debt Debt-to-Equity RatioN/A Current Ratio10.28 Quick Ratio10.28 Sales & Book Value Annual Sales$168.65 million Price / Sales4.79 Cash Flow$0.25 per share Price / Cash Flow27.05 Book Value$5.12 per share Price / Book1.30Miscellaneous Outstanding Shares121,550,000Free FloatN/AMarket Cap$808.31 million OptionableOptionable Beta0.93 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:IMTX) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.